English
Back

Li Ankang, CFO & CSO of Tengsheng Pharmaceuticals: I am very interested in changes in the central nervous system and infections

avatar
BRII wrote a column · Jan 18, 2022 19:06
Source: Medical Rubik's Cube
The JP Morgan Healthcare Conference (JP Morgan Healthcare Conference) is an annual event where industry and capital are closely integrated: there are large pharmaceutical companies presenting their business development strategies to global investors, and many high-quality small biomedical companies seeking partners with projects. In the past, executives from world-renowned pharmaceutical/biotech companies, investment banks, consulting firms, accounting firms, law firms, etc. flew to San Francisco from all over the world at the beginning of January every year.
This year's JPM conference was held online due to the impact of the epidemic. Participants mainly collided with projects and capital in the “cloud”. Peers experienced the popularity of the industry and collided with the spark of wisdom in parallel time and space. Pharmaceutical Rubik's Cube took this opportunity to interview the CFO or BD leader of a well-known pharmaceutical company in the industry to see the gains and inspiration that JP.Morgan brought to the industry from their perspective.
The following is$BRII-B(02137.HK)$ A transcript of Dr. Li Ankang, Chief Financial Officer and Chief Strategy Officer (CFO & CSO), being interviewed by Pharmaceutical Rubik's Cube. Lee An-kang is a “double” doctorate in law from the University of Chicago Law School and biomedicine from Baylor College of Medicine in the US. He is currently mainly responsible for the company's finance and finance, financial reporting and risk control, legal affairs, investor relations, corporate communications, and corporate operation and development strategies.
Dr. Lee An-kang
Dr. Lee An-kang
Medical Rubik's Cube:When did you start following JPM? What was the reason for your attention at the time?
Lee An-kang: As the most important industrial and investment communication feast in the global healthcare industry, JPM showcased a world-class platform where industry and capital were integrated and linked at the first and second levels. It provided an excellent collision opportunity for startups, technology platform companies, and large pharmaceutical companies and investors, leading the development and investment direction of the global healthcare sector.
I've been watching and participating in JPM in a different capacity and perspective since about 7 or 8 years ago until now. I first worked as a lawyer focusing on life science transactions, focusing on industry trends and important transactions. Later, while working at MSD's Asia Pacific Innovation Center (known as Merck in the US and Canada), I represented MSD in discussions with potential partners on possible licensing cooperation during the JPM conference.
Then, in the investment bank and in my current career as CFO of Tengsheng Pharma, I also participated in the company's communication with investors and partners from different perspectives. Whether it's the strategic layout of industry giants or the capital market enabling R&D and innovation, I can draw rich and valuable experience from it and strive to enhance the company's vitality and competitiveness in the industry.
Medical Rubik's Cube:What have you learned from JPM? There are more and more similar exchange activities in China. In your opinion, what are the advantages and disadvantages?
Lee An-kang:The benefits can be mainly divided into cognitive and business gains.
At the cognitive level, leading pharmaceutical companies and emerging biotechnology companies at the JPM conference will all share their plans and major anticipated R&D progress for the next year. These are all important directions and events that the industry needs to pay attention to, and are of great reference value for us to think deeply about the layout and strategies of related fields.
At the business level, licensing and cooperation are important value catalysts in the biomedical field. And the JPM conference has always been the biggest stage for exchange and cooperation. Many important cooperative transactions and mergers and acquisitions in the industry will be negotiated or announced during the JPM conference.
There have also been more and more domestic similar industry conferences in the past few years, and the scale is not small, but there is no such thing as the JPM conference that is recognized as the most representative pharmaceutical conference. There are many reasons. For example, the biomedical industry is still in the early stages of development, and the number is still far smaller than in the US. The capital market is also far from mature. But I believe that with enough time in the country, there will definitely be a first-class industry conference like the JPM Conference.
Medical Rubik's Cube:Did the company participate in the JPM conference this year and use this platform to achieve what goals?
Li Ankang:We, Tengsheng Pharmaceuticals, mainly participated in JPM remotely this year in the form of one-on-one communication with investors and potential partners. As a young biomedical company, our main hope in participating in JPM is to let more people know about our company, understand our product pipeline, and find opportunities for cooperation.
Medical Rubik's Cube:What are some of the most impressive deals around JPM this year?
Li Ankang:I think the most representative ones are several multinational pharmaceutical companies continuing to invest in new technology, new modality, and new treatment methods. Examples include Bayer's collaboration on gene editing, Novartis's collaboration with Alnylam in the field of siRNA, and cooperation between AstraZeneca and Amgen in AI drug development. These all represent methods, technologies, and molecular types that are different from traditional drug development in pharmaceutical research and development, and have the potential to bring about greater industry breakthroughs.
Medical Rubik's Cube:What areas of cooperation/technical progress are you focusing on?
Lee An-kang: Tengsheng Pharmaceuticals focuses on the field of diseases with major public health challenges, and is committed to innovative treatments to contribute to human health. Our main focus on external cooperation is cooperation on some new treatment models and platform-based technologies. From the field of diseases, we are most interested in central nervous system diseases and infectious diseases.
Hong Kong stocks
Main shares
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty. Read more
1
1
+0
3
See Original
Report
24K Views
Comment
Sign in to view/post comments
avatar
The official account of Brii Biosciences Limited
80KFollowers
113KVisitors
Follow